New Genentech Study to Investigate Familial Alzheimer’s Progression and Response to Crenezumab

New Genentech Study to Investigate Familial Alzheimer’s Progression and Response to Crenezumab
Genentech, a subsidiary of Roche, has launched a new substudy to learn more about the progression of early-onset familial Alzheimer’s disease, as part of its ongoing Alzheimer’s Prevention Initiative (API) trial evaluating crenezumab for preventing or delaying this genetic form of the disease. This substudy will examine the effects of presymptomatic treatment with crenezumab — an investigational anti-amyloid antibody under development by AC Immune and Genentech — on tau accumulation in the brains of patients at risk of familial Alzheimer’s. Data is expected to advance the understan
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *